Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
108,90 €
-0,41 %
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $154.00 to $148.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $170.00 to $200.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $148.00 to $158.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $200.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at HC Wainwright from $150.00 to $160.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $200.00 to $216.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Barclays PLC from $150.00 to $169.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Guggenheim from $164.00 to $170.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $175.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at UBS Group AG from $174.00 to $193.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $152.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $160.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $169.00 to $173.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Morgan Stanley from $160.00 to $170.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
Cantor_Fitzgerald in Discuss Western Digital Corp.